Physician profile
Stefan A Swicker
NPI 1629060819
$3,766.76
in general payments reported to CMS, 2019-2025
23 companies · $814 in 2025
The $814 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $171 · 2021: $62.40 · 2022: $431 · 2023: $821 · 2024: $1,201 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $728.82 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $509.43 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $447.50 | 2019-2025 | Yeztugo |
| Novo Nordisk INC | $323.29 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $309.68 | 2020-2025 | Bexsero, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $296.86 | 2019-2025 | Capvaxive, M-M-R II, Gardasil 9 |
| Exact Sciences Corporation | $156.27 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $138.69 | 2022-2024 | |
| Pfizer INC. | $137.57 | 2023-2025 | |
| Astellas Pharma US INC | $114.88 | 2023-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $105.65 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $103.97 | 2019-2024 | |
| Amgen INC. | $103.40 | 2019-2025 | Repatha, Otezla, Evenity |
| Viiv Healthcare Company | $54.09 | 2023-2024 | Apretude |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.21 | 2023 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $34.63 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Seqirus USA INC | $28.39 | 2024 | Fluad, Flucelvax |
| Shield Therapeutics INC | $26.25 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.45 | 2023 | |
| Axsome Therapeutics, INC. | $25.02 | 2025 | Auvelity |
| Abbott Laboratories | $22.67 | 2023 | Freestyle Libre 2 |
| Ibsa Pharma INC. | $17.83 | 2024 | Licart, Tirosint |
| Kaleo, INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Swicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.